These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15864230)

  • 1. Coronary drug-eluting stent development: issues in trial design.
    Muni NI; Califf RM; Foy JR; Boam AB; Zuckerman BD; Kuntz RE
    Am Heart J; 2005 Mar; 149(3):415-33. PubMed ID: 15864230
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis.
    Vaina S; Ong AT; Serruys PW
    Minerva Cardioangiol; 2005 Oct; 53(5):341-60. PubMed ID: 16179880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease.
    Kohn J; Zeltinger J
    Expert Rev Med Devices; 2005 Nov; 2(6):667-71. PubMed ID: 16293093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-stent restenosis in idiopathic isolated ostial left main coronary artery stenosis.
    Jim MH; Yiu KH; Chow WH
    Int J Cardiol; 2007 Jan; 114(3):e111-3. PubMed ID: 17049638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
    Sabaté M; Jiménez-Quevedo P; Angiolillo DJ; Gómez-Hospital JA; Alfonso F; Hernández-Antolín R; Goicolea J; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Circulation; 2005 Oct; 112(14):2175-83. PubMed ID: 16203930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel-eluting balloon: from bench to bed.
    De Labriolle A; Pakala R; Bonello L; Lemesle G; Scheinowitz M; Waksman R
    Catheter Cardiovasc Interv; 2009 Apr; 73(5):643-52. PubMed ID: 19309715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stents: beyond the hyperbole.
    Hunter WL
    Adv Drug Deliv Rev; 2006 Jun; 58(3):347-9. PubMed ID: 16600419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strut fracture of DES: an increasing problem?
    Jin X; Zhang S; Xie H; Wang C; Fan Z; Zeng Y; Shen Z; Fang Q
    Int J Cardiol; 2007 May; 118(2):e54-6. PubMed ID: 17395294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting stents: a multidisciplinary success story.
    Burt HM; Hunter WL
    Adv Drug Deliv Rev; 2006 Jun; 58(3):350-7. PubMed ID: 16546288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting stents: a pharmacoclinical perspective.
    Thomas MK; Gupta YK
    Natl Med J India; 2006; 19(4):195-9. PubMed ID: 17100106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-stent pseudo-restenosis due to an organized thrombus six months after implantation of a sirolimus-eluting stent.
    Murasato Y; Okamatsu K
    J Invasive Cardiol; 2007 Mar; 19(3):145-8. PubMed ID: 17341784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
    Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A
    Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
    Morice MC; Serruys PW; Barragan P; Bode C; Van Es GA; Stoll HP; Snead D; Mauri L; Cutlip DE; Sousa E
    J Am Coll Cardiol; 2007 Oct; 50(14):1299-304. PubMed ID: 17903626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based medicine and drug-eluting stents.
    O'Dwyer J
    Med Device Technol; 2004 May; 15(4):34-7. PubMed ID: 15303564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model.
    Bhargava B; Reddy NK; Karthikeyan G; Raju R; Mishra S; Singh S; Waksman R; Virmani R; Somaraju B
    Catheter Cardiovasc Interv; 2006 May; 67(5):698-702. PubMed ID: 16575925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering aspects of stents design and their translation into clinical practice.
    Sangiorgi G; Melzi G; Agostoni P; Cola C; Clementi F; Romitelli P; Virmani R; Colombo A
    Ann Ist Super Sanita; 2007; 43(1):89-100. PubMed ID: 17536159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
    Urban P; Gershlick AH; Guagliumi G; Guyon P; Lotan C; Schofer J; Seth A; Sousa JE; Wijns W; Berge C; Deme M; Stoll HP;
    Circulation; 2006 Mar; 113(11):1434-41. PubMed ID: 16534015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.